Introduction and objectives
Aim of the study was to review the quality, safety, and efficacy of medical cannabis (MC). Botanical, regulatory and social-epidemiological aspects were included. 
Methods 
We did a search of PubMed, Elsevier, and the Cochrane databases up to 30th of April, 2019 using “cannabis”, “cannabinoids” as keywords. We identified 29 clinical trials and 17 epidemiological studies meeting our inclusion criteria.
Results
568 molecules and 104 cannabinoids are identified from Cannabis. Number of pharmaceutical forms are available including capsules, tinctures, oils, dermal patches, sprays, smoking formulations. The variety of active compounds and absence of pharmacopoeia articles for quality standardization makes difficult to classify and study safety and efficacy of MC in pain control. In the latest research, MC based therapy reduced pain 10,7% compared to placebo (4,5%) using VAS in patients with chronic pain, however some studies showed no change. Nabiximols showed reduction in muscle spasms by 1.3 compared to placebo - 0.4 points. Consumption of marijuana in US by 2004 reached 7.13% in states with and 3.57% without medical cannabis laws (MCL) as well as marijuana abuse 1,27% and 2,61% respectively. In 2016 Israel became the leading country for cannabis consumption as the prevalence rate after MCL implementation reached 27% of the entire adult population. (Fig. 2) Cannabis was well tolerated and effectively reduced pain for patients with neuropathy. Moreover, it effectively reduced pain and muscles spasms for patients with multiple sclerosis. (Fig. 3)
Conclusions
MC products may reduce usage for pain control medicines, but larger-scale clinical trials are necessary to prove therapeutic benefits to different types of pain, as well as define exact dosage and implement pharmacopeia monographs standardization. MC legalization causes the increase of cannabis abuse and it may negatively affect public health situation on a country level.

ROLE OF CANNABIS AND CANNABINOIDS IN PAIN MANAGEMENT AND SOCIAL ASPECTS OF MEDICAL CANNABIS LEGALIZATION